Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Karl D. Lewis, MD, on the Role of Adjuvant Immunotherapy in NMSC

Posted: Monday, September 23, 2019

What is the future role for adjuvant treatment with cemiplimab, particularly in high-risk groups of patients with nonmelanoma skin cancer?



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.